Quetiapine (Seroquel®)

Quetiapine is an atypical antipsychotic drug that is used to treat schizophrenia and bipolar disorders. It is referred to as an atypical antipsychotic because of its lesser propensity to cause extrapyramidal effects. It has high affinity for serotonergic type 2 receptors and a moderate affinity for dopamine type 2 receptors.

Seroquel is completely and rapidly absorbed after oral administration and undergoes significant first-pass hepatic metabolism. It has a large volume of distribution, is highly protein bound and accumulates in the brain. Plasma concentrations with therapeutic dosing are quite low. Following oral administration, peak plasma concentrations of quetiapine are reached in 1.5 hours for regular release tablets and in 6 hours for extended release. It is metabolized in the liver via the cytochrome P450 enzymes CYP3A4 and CYP2D6. Other medications that inhibit or stimulate the activity of these two cytochrome P450 enzymes may increase or decrease serum quetiapine levels.

QUETIAPINE OVERDOSE

Signs and Symptoms

Mild to moderate quetiapine overdoses can show the anticholinergic symptoms of dry mouth, constipation, somnolence, dizziness, and mild sinus tachycardia. Severe quetiapine poisoning can result in significant CNS depression, sinus tachycardia, and urinary retention. Mild hypotension, QTc prolongation, elevated liver enzymes, seizures and myoclonic jerks may also be observed. Respiratory depression frequently occurs with massive overdoses.

Treatment

Symptomatic and supportive care is the mainstay of treatment for quetiapine overdoses. Monitor vital signs and mental status. Hypotension will usually respond to fluid resuscitation. Replete K⁺, Ca²⁺ and Mg²⁺ for QTc prolongation. Monitor creatine phosphokinase in patients with prolonged CNS depression, seizures or myoclonus. Quetiapine plasma levels are not readily available nor clinically useful in treating overdose. In large overdoses, quetiapine elimination may be prolonged due to its ongoing absorption, the anticholinergic effect, and its large volume of distribution.

Thomas Esslinger, RN, CSPI
Certified Specialist in Poison Information

Hotline Editor: Edward Bottei, MD
Post and share this edition of Poison Hotline with your colleagues. Send comments or questions to Poison Hotline, 712-234-8775 (fax) or Tammy.Noble@UnityPoint.org. To subscribe or unsubscribe from this distribution list, contact the IPCC education office at 712-279-3717. Read past issues of Poison Hotline at www.iowapoison.org.